Novartis expands skin care portfolio with Ziarco Group acquisition

Basel, Switzerland-based Novartis on Friday entered into a definitive agreement to acquire Ziarco Group.

Ziarco Group is a privately held biotechnology company focused on treatments for inflammatory skin disorders.

Through the deal, Novartis will gain access to Ziarco's investigational oral treatment for moderate-to-severe eczema.

Financial details of the transaction were not disclosed.

More articles on supply chain:

McKesson, Infor form go-to-market partnership: 3 things to know
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars